Trials / Completed
CompletedNCT04473274
GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Samaritan Health Services · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pioglitazone is an approved anti-hyperglycemic medication and is thought to have anti-inflammatory properties. This study seeks to gather safety and tolerability data related to pioglitazone when given to patients who require hospital admission for confirmed positive COVID-19 infections with elevated blood sugar levels as compared to patients who did not receive pioglitazone during their hospitalization for COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pioglitazone | Receive pioglitazone 15mg - 30mg daily |
Timeline
- Start date
- 2020-05-21
- Primary completion
- 2020-11-01
- Completion
- 2020-12-01
- First posted
- 2020-07-16
- Last updated
- 2020-12-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04473274. Inclusion in this directory is not an endorsement.